Advertisement
News
Subscribe to MDT Magazine News

Bexion Pharmaceuticals Receives Outstanding Biotech Innovation Award

April 18, 2011 11:33 am | by Bio-Medicine.Org | Comments

COVINGTON, Ky., April 18, 2011 /- Bexion Pharmaceuticals was named the Biotech Innovation Award winner at the Cincinnati USA Innovation Awards program sponsored by the Cincinnati Business Courier, the Cincinnati USA Regional Chamber and CincyTech.  The Innovation Awards celebrate...

TOPICS:

New Orleans Employees' Retirement System Announces Settlement of Celera Takeover Litigation

April 18, 2011 10:45 am | by The Associated Press | Comments

The New Orleans Employees' Retirement System ("NOERS"), the Court-appointed lead plaintiff in the case pending in Delaware Chancery Court captioned In re Celera Corporation Shareholder Litigation, Consol. C.A. No. 6304-VCP, is pleased to announce that it has approved a settlement of the...

New pollutants detected in peregrine falcon eggs

April 18, 2011 10:37 am | by EurekAlert | Comments

(FECYT - Spanish Foundation for Science and Technology) Flame retardants are chemical compounds added to fabrics and plastics to keep them from burning easily, but these can be toxic. Now a team of researchers from Spain and Canada has detected some of these emerging pollutants for...

TOPICS:
Advertisement

Microelectromechanical switch-on: Carbon nanotube switches

April 18, 2011 10:37 am | by I-Micronews | Comments

Korean researchers make a tiny switch from carbon nanotubes.

The city college of New York set up a new metamaterials center

April 18, 2011 10:37 am | by I-Micronews | Comments

A new industry and university cooperative research center proposes to provide a one-stop shop for the design, fabrication and testing of a wide range of metamaterials designed to aid solar photovoltaic systems, specialized light sensors and more.

Patent attorney Ginsburg joins Cellceutix advisory board

April 18, 2011 9:40 am | by Mass High Tech: The Journal of New England Technology | Comments

Cellceutix Corp. , a Beverly biopharmaceutical company, has named patent attorney Paul Ginsburg to the company's advisory board.

FDA officially rejects Lilly, Alnara CF drug

April 18, 2011 9:40 am | by Mass High Tech: The Journal of New England Technology | Comments

In a widely expected move, the U.S. Food and Drug Administration has rejected a drug to treat Cystic Fibrosis made by Alnara Pharmaceuticals, which is owned by Indianapolis-based Eli Lilly and Co. The FDA has ordered additional clinical trials to further study the drug candidate, called liprotamase.

Idera reports progress on gene-silencing

April 18, 2011 9:39 am | by Mass High Tech: The Journal of New England Technology | Comments

Cambridge's Idera Pharmaceuticals Inc. (Nasdaq: IDRA) today reported that studies show its gene-silencing oligonnucleotides (GSOs) efficiently inhibited gene expression, overcoming issues associated with other gene-silencing technologies, such as stability, specificity and system delivery.

Advertisement

American Scientific Resources, Inc. Announces Corporate Update

April 18, 2011 9:38 am | by Bio-Medicine.Org | Comments

WESTON, Fla., April 18, 2011 /- American Scientific Resources, Incorporated (OTCQB: ASFXD) today announces the posting of a Corporate Update for Shareholders now available for perusal on the company web site,...

TOPICS:

FDA News & Notes - Week of April 18, 2011

April 18, 2011 9:38 am | by Bio-Medicine.Org | Comments

SILVER SPRING, Md., April 18, 2011 /PRNewswire-USNewswire/ -- Science, public health, and regulatory highlights for this week from the U.S. Food and Drug Administration. I nformation in this document is designed for credentialed journalists. Release dates and times for items are current...

TOPICS:

Amarin says treatment cuts triglycerides in Phase 3 trial

April 18, 2011 9:36 am | by Mass High Tech: The Journal of New England Technology | Comments

Amarin Corp., an Irish biopharmaceutical with U.S. operations in Mystic, Conn., said today that its drug candidate AMR101 showed significant decreases in triglycerides during a Phase 3 trial.

TOPICS:

JCI online early table of contents: April 18, 2011

April 18, 2011 8:38 am | by EurekAlert | Comments

(Journal of Clinical Investigation) This release contains the summaries, titles and author contact information for articles to be released in the April 18 edition of the JCI, including "Why the immune system attacks beta cells in Type 1 diabetes"; "Could a liver cell transplant...

TOPICS:

Manufacturers to Discover Latest Technologies at HOUSTEX April 18-20, George R. Brown Convention Center

April 18, 2011 8:37 am | by Society of Manufacturing Engineers | Comments

DEARBORN, Mich., April 18, 2011 — With the manufacturing sector leading the country's economic recovery, it is imperative for manufacturers to stay on top of the latest technologies and processes. With more than 13,000 manufacturing and engineering companies in the greater Houston...

Study Finds Exergen Temporal Artery Thermometry Accurate on Newborns

April 18, 2011 8:34 am | by Bio-Medicine.Org | Comments

WATERTOWN, Mass., April 18, 2011 /- Measuring the body temperatures of newborns with temporal artery thermometry (forehead scanning) provides readings comparable to results obtained by axillary (under arm) thermometry, the clinically recommended method for this patient population, but...

TOPICS:

Bedford Laboratoriesâ„¢ to Begin Shipping Topotecan Hydrochloride for Injection, 4mg SD Vial

April 18, 2011 8:34 am | by Bio-Medicine.Org | Comments

BEDFORD, Ohio,  April 18, 2011 /- Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Topotecan Hydrochloride for Injection, 4 mg (base)/vial to its diverse portfolio.  Topotecan is AP Bioequivalent to the reference...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading